Karadag, O. Et Al. 2024. Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.. Clinical and experimental rheumatology , vol.42 , 130-137.

Karadag, O., Farisogullari, B., Yagiz, B., Erden, A., Ademoglu, Z., Kimyon, G., ... Bilge, N. S.(2024). Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.. Clinical and experimental rheumatology , vol.42, 130-137.

Karadag, Omer Et Al. "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.," Clinical and experimental rheumatology , vol.42, 130-137, 2024

Karadag, Omer Et Al. "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.." Clinical and experimental rheumatology , vol.42, pp.130-137, 2024

Karadag, O. Et Al. (2024) . "Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.." Clinical and experimental rheumatology , vol.42, pp.130-137.

@article{article, author={Omer Karadag Et Al. }, title={Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying anti-rheumatic drugs: real life experience from the TReasure Registry.}, journal={Clinical and experimental rheumatology}, year=2024, pages={130-137} }